Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Goldman Sachs Raises Oil Price Forecasts Amid Strait of Hormuz Disruptions 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
Elon Musk Announces Terafab: SpaceX and Tesla to Build Dual AI Chip Factories in Austin, Texas 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
Air Canada Express Plane Collides with Ground Vehicle at LaGuardia Airport 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
U.S. Stock Futures Slide as Iran Conflict and Inflation Fears Rattle Wall Street 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Iran-Israel War Escalates: Long-Range Missiles, Nuclear Site Strikes, and Global Energy Crisis 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
OpenAI's Desktop Superapp: Unifying ChatGPT, Codex, and Browser Tools for Enterprise AI 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Trump Signals End of U.S. Military Campaign Against Iran as Markets Rally 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Celltrion, a South Korean pharmaceutical company, revealed on Thursday, Aug. 12, that it has received emergency approval from the government of Brazil for its COVID-19 antibody treatment.
According to The Korea Herald, Celltrion shared that the Health Regulatory Agency of the said country granted emergency use authorization (EUA) for its Regkirona or CT-P59, which is a COVID-19 treatment. It was said that the agency made the decision based on the results of the drug’s clinical tests for all three phases.
Celltrion added that the Brazilian health agency also looked into their preclinical studies that show the efficacy of the treatment against COVID-19 variants. Once it is made available in Brazil, Regkirona will be utilized for the treatment of adult patients who are at higher risk from COVID-19 and experiencing both mild and severe symptoms.
Korea Biomedical Review reported that adults aged 65 or older with mild and moderate symptoms would also be treated with Celltrion’s antibody drug. With the high number of daily coronavirus cases in Brazil today, Celltrion said it will deliver Rekirona to the country as fast as it could to help treat the patients.
In the COVID-19 world statistics on Worldometer, Brazil has more than 20 million cases of coronavirus infection and more than 560,000 deaths. With the spread of the more contagious Delta variant, the country is recording daily cases of around 10,000 to 30,000.
“Based on the safety and efficacy proven through large-scale global clinical data of Regkirona, the company has obtained emergency use approval from the Brazilian health authorities,” a Celltrion official stated. “We will do our best to contribute to preventing the spread of Covid-19 by supplying Regkirona early to Brazil, where the number of confirmed cases has recently rapidly increased to 30,000 a day due to the spread of the Delta variant.”
Celltrion declared that its Rekirona antibody treatment drug could reduce the risk of the coronavirus infection from progressing to a severe stage. The pharmaceutical firm further said that it could lessen the recovery time as well. Meanwhile, with the Brazilian EUA, Celltrion is planning to submit an application for similar authorization in the U.S.
